Good morning. Elizabeth Cooney here again, subbing for the vacationing Ed Silverman as the week really gets going. Let’s have some news with our coffee.
A Covid-19 vaccine being developed by Oxford University and the drug giant AstraZeneca (AZN) generated an immune response in a study of roughly 1,000 patients, according to interim results, the first glimpse researchers have gotten at its efficacy, STAT reports. The data show a relatively safe vaccine, although side effects were greater than for a meningitis vaccine to which it was compared. AstraZeneca said it is likely that future studies will test giving patients two doses of the vaccine.